@article{PCM5169,
author = {Xuan Ge and Sara Tariq and Haiying Cheng and Balazs Halmos},
title = {Targeting ErbB2 aberrations in non-small cell lung cancer},
journal = {Precision Cancer Medicine},
volume = {2},
number = {0},
year = {2019},
keywords = {},
abstract = {Human epidermal growth factor 2 (HER2 or ErbB2) mutations in lung cancer are oncogenic drivers similar to epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers. Until recently, ErbB2-mutant lung cancers have generally been resistant to various targeted agents. However, a new wave of ErbB2-targeting drugs has shown promise for this subset. We highlight a case of a patient with an ErbB2-mutant lung cancer with an exon 20 YVMA insertion who had a good response to poziotinib and review the current literature on the methods of testing for ErbB2 mutations and the efficacy of various known and emerging targeted agents.},
issn = {2617-2216}, url = {https://pcm.amegroups.org/article/view/5169}
}